Download PDF
Exp Clin Endocrinol Diabetes 2016; 124(07): 444-447
DOI: 10.1055/s-0042-108447
Article
© Georg Thieme Verlag KG Stuttgart · New York

Serum Paraoxonase-1 Levels are Significantly Decreased in the Presence of Insulin Resistance

A. Gateva
1   Department of Internal Medicine, Medical University – Sofia, Clinic of Endocrinology, University Hospital “Alexandrovska”, Sofia, Bulgaria
,
Y. Assyov
1   Department of Internal Medicine, Medical University – Sofia, Clinic of Endocrinology, University Hospital “Alexandrovska”, Sofia, Bulgaria
,
A. Tsakova
2   Department of Clinical Laboratory and Immunology, Medical University – Sofia, Central Clinical Laboratory, University Hospital “Alexandrovska”, Sofia, Bulgaria
,
Z. Kamenov
1   Department of Internal Medicine, Medical University – Sofia, Clinic of Endocrinology, University Hospital “Alexandrovska”, Sofia, Bulgaria
› Author Affiliations
Further Information

Publication History

received 16 February 2016
revised 10 May 2016

accepted 11 May 2016

Publication Date:
29 June 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Paraoxonase-1 (PON1) is an extracellular esterase contributing to the anti-atherogenic and anti-inflammatory properties of HDL and has a protective role in the progression of atherosclerosis. The aim of the present study was to compare serum paraoxonase-1 levels between obese subjects with prediabetes and normal glucose tolerance.

Methods: In this study were included 76 patients with mean age 50.7±10.7 years, divided into 2 age and BMI-matched groups – group 1 with obesity without glycemic disturbances (n=38) and group 2 with prediabetes (n=38). Oral glucose tolerance test (OGTT) with measurement of immunoreactive insulin was performed in all participants and levels of PON1 were measured using ELISA method.

Results: There was only a tendency towards higher PON1 levels in patients with prediabetes compared to controls. However, individuals with insulin resistance had significantly lower levels of PON1 compared to those without. The levels of PON1 showed a negative correlation with the blood glucose on 120th minute of OGTT, fasting IRI, HOMA index, BMI, WSR, WHR and particularly with waist circumference and positive with HDL-cholesterol.

Conclusions: The levels of PON1 are similar in patients with and wthout prediabetes, but are significantly decreased in patients with insulin resistance and correlate with anthropometric markers of visceral adiposity.

Key words

prediabetes - cardiovascular complications - paraoxonase - insulin reisistance
 

  • References

  • 1 de Vegt F, Dekker JM, Jager A et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population; The Hoorn study. JAMA 2001; 285: 2109-2113
    CrossrefPubMedGoogle Scholar
  • 2 Shaw JE, Zimmet PZ, de Courten M et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritus?. Diabetes care 1999; 22: 399-402
    CrossrefPubMedGoogle Scholar
  • 3 The DECODE Study Group . Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 2003; 26: 688-696
    CrossrefPubMedGoogle Scholar
  • 4 The DECODE study group . European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354: 617-621
    CrossrefPubMedGoogle Scholar
  • 5 Ning F, Tuomilehto J, Pyorala K et al. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 2010; 33: 2211-2216
    CrossrefPubMedGoogle Scholar
  • 6 Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010; 55: 1310-1317
    CrossrefPubMedGoogle Scholar
  • 7 Qureshi AI, Giles WH, Croft JB. Impaired glucose tolerance and the likelihood of nonfatal stroke and myocardial infarction: the Third National Health and Nutrition Examination Survey. Stroke 1998; 29: 1329-1332
    CrossrefPubMedGoogle Scholar
  • 8 Durrington PN, Mackness B, Mackness M. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-480
    CrossrefPubMedGoogle Scholar
  • 9 Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154
    CrossrefPubMedGoogle Scholar
  • 10 Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009; 46: 83-106
    Google Scholar
  • 11 Bhattacharyya T, Nicholls SJ, Topol EJ et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA: the journal of the American Medical Association. 2008. 299. 1265-1276
    Google Scholar
  • 12 Gupta N, Binu KB, Singh S et al. Low serum PON1 activity: an independent risk factor for coronary artery disease in North-West Indian type 2 diabetics. Gene 2012; 498: 13-19
    CrossrefPubMedGoogle Scholar
  • 13 Mackness B, Davies GK, Turkie W et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 2001; 21: 1451-1457
    CrossrefPubMedGoogle Scholar
  • 14 Ayub A, Mackness MI, Arrol S et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-335
    CrossrefPubMedGoogle Scholar
  • 15 Bounafaa A, Berrougui H, Ghalim N et al. Association between Paraoxonase 1 (PON1) Polymorphisms and the Risk of Acute Coronary Syndrome in a North African Population. PLoS One 2015; 10: e0133719
    CrossrefPubMedGoogle Scholar
  • 16 Ikeda Y, Inoue M, Suehiro T et al. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol 2009; 46: 239-242
    CrossrefPubMedGoogle Scholar
  • 17 Zsíros N, Koncsos P, Lőrincz H et al. Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications. Clin Biochem 2016; [Epub ahead of print]
    PubMedGoogle Scholar
  • 18 Ozgun E, Ozgun GS, Gokmen SS et al Effect of Lipoic Acid on Serum Paraoxonase-1 and Paraoxonase-3 Protein Levels and Activities in Diabetic Rats. Exp Clin Endocrinol Diabetes 2016; [Epub ahead of print]
    PubMedGoogle Scholar
  • 19 Tabur S, Sezen H, Korkmaz H et al. High Prolidase Levels may be a Marker of Irreversible Extracellular Matrix Changes in Controlled Acromegaly Patients?. Exp Clin Endocrinol Diabetes 2016; 124: 82-86
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Arancibia C, Galgani J, Valderas JP et al. Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance. Rev Med Chil 2014; 142: 1106-1112
    CrossrefPubMedGoogle Scholar
  • 21 Ascaso J, Pardo S, Real JT et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320-3325
    CrossrefPubMedGoogle Scholar
  • 22 Levitan EB, Song Y, Ford ES et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004; 164: 2147-2155
    CrossrefPubMedGoogle Scholar
  • 23 Wen CP, Cheng TY, Tsai SP et al. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 2005; 28: 2756-2761
    CrossrefPubMedGoogle Scholar
  • 24 Ferretti G, Bacchetti T, Moroni C et al. Paraoxonase activity in highdensity lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005; 90: 1728-1733
    CrossrefPubMedGoogle Scholar
  • 25 Kopprasch S, Pietzsch J, Kuhlisch E et al. Chemiluminescence as a tool to assess hyperglycemia-induced systemic oxidative stress in different insulinresistant states. Abstracts of the 12th International Symposium on Bioluminescence and Chemiluminescence, Cambridge Luminescence 2002; 17: 94
    PubMedGoogle Scholar
  • 26 Kopprasch S, Pietzsch J, Kuhlisch E et al. Lack of Association between Serum Paraoxonase 1 Activities and Increased Oxidized Low-Density Lipoprotein Levels in Impaired Glucose Tolerance and Newly Diagnosed Diabetes Mellitus. J Clin Endocrinol Metab 2003; 88: 1711-1716
    CrossrefPubMedGoogle Scholar
  • 27 Yamada A, Shoji T, Tahara H et al. Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population. Metabolism 2001; 50: 805-811
    CrossrefPubMedGoogle Scholar
  • 28 Dursun P, Demirtas E, Bayrak A et al. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS?. Human Reproduction 2006; 21: 104-108
    CrossrefPubMedGoogle Scholar